126 related articles for article (PubMed ID: 38679928)
1. Optimal follow-up with somatostatin receptor PET/CT imaging in patients with small intestinal neuroendocrine tumours.
Ohlsson H; Spaak E; Gålne A; Sundlöv A; Almquist M
J Neuroendocrinol; 2024 Apr; ():e13396. PubMed ID: 38679928
[TBL] [Abstract][Full Text] [Related]
2. Imaging surveillance in multiple endocrine neoplasia type 1: Ten years of experience with somatostatin receptor positron emission tomography.
Said M; Krogh J; Feldt-Rasmussen U; Rasmussen ÅK; Kristensen TS; Rossing CM; Johannesen HH; Oturai P; Holmager P; Kjaer A; Klose M; Langer S; Knigge U; Andreassen M
J Neuroendocrinol; 2023 Aug; 35(8):e13322. PubMed ID: 37564005
[TBL] [Abstract][Full Text] [Related]
3. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
4. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
Tirosh A; Nilubol N; Patel D; Kebebew E
Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total
Tirosh A; Papadakis GZ; Millo C; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
Eur J Endocrinol; 2017 May; 176(5):575-582. PubMed ID: 28289088
[TBL] [Abstract][Full Text] [Related]
9. Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2.
Papantoniou D; Grönberg M; Landerholm K; Welin S; Ziolkowska B; Nordvall D; Janson ET
Endocrine; 2021 Jun; 72(3):893-904. PubMed ID: 33244704
[TBL] [Abstract][Full Text] [Related]
10. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
Hindié E
Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
13. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
Pfeifer A; Knigge U; Mortensen J; Oturai P; Berthelsen AK; Loft A; Binderup T; Rasmussen P; Elema D; Klausen TL; Holm S; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
[TBL] [Abstract][Full Text] [Related]
14. PET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study.
Frumovitz M; Morani AC; Aziz A; Jhingran A; Ramalingam P; Gonzales NR; Salvo G; Sun J; Bhosale P
Int J Gynecol Cancer; 2023 Nov; 33(11):1690-1694. PubMed ID: 37875320
[TBL] [Abstract][Full Text] [Related]
15. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
16. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India.
Pruthi A; Pankaj P; Verma R; Jain A; Belho ES; Mahajan H
J Gastrointest Oncol; 2016 Jun; 7(3):449-61. PubMed ID: 27284479
[TBL] [Abstract][Full Text] [Related]
17.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of
Gabriel S; Garrigue P; Dahan L; Castinetti F; Sebag F; Baumstark K; Archange C; Jha A; Pacak K; Guillet B; Taïeb D
Clin Endocrinol (Oxf); 2018 Aug; 89(2):155-163. PubMed ID: 29788534
[TBL] [Abstract][Full Text] [Related]
19. The Impact of
Cuthbertson DJ; Barriuso J; Lamarca A; Manoharan P; Westwood T; Jaffa M; Fenwick SW; Nuttall C; Lalloo F; Prachalias A; Pizanias M; Wieshmann H; McNamara MG; Hubner R; Srirajaskanthan R; Vivian G; Ramage J; Weickert MO; Pritchard DM; Vinjamuri S; Valle J; Yip VS
Front Endocrinol (Lausanne); 2021; 12():654975. PubMed ID: 34163434
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
Basu S; Ranade R; Thapa P
World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
